Dyadic International, Inc. (DYAI) vs Neuphoria Therapeutics Inc. (NEUP)
A side-by-side comparison of Dyadic International, Inc. and Neuphoria Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
DYAI
Dyadic International, Inc.
$0.45HealthcareDelayed quote: Oct 6, 2026, 12:20 PM EDT
NEUP
Neuphoria Therapeutics Inc.
$3.49HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — DYAI vs NEUP
growth of $100 · dividends reinvested · last 5yDYAI -88.5% (-35.1%/yr)NEUP -98.0% (-54.5%/yr)DYAI compounded faster over this window
Log scale — wide-divergence pair
DYAI NEUP
DYAI vs NEUP: by the numbers
- •NEUP is the larger company ($19M vs $16M market cap).
- •Both run net losses; DYAI's is the smaller (-219.50% vs -1578.40% net margin).
- •NEUP grew revenue faster over the past five years (11.12% vs -5.11% CAGR).
Metrics side by side
Valuation
| Metric | DYAI | NEUP |
|---|---|---|
| P/S ratio | 4.75 | 16.06 |
| P/B ratio | N/A | 0.77 |
Profitability
| Metric | DYAI | NEUP |
|---|---|---|
| Gross margin | -88.25% | 43.54% |
| Operating margin | -579.88% | -835.53% |
| Net margin | -219.50% | -1578.40% |
| ROE | N/A | -75.34% |
| ROIC | -279.48% | -49.83% |
Growth (annualized)
| Metric | DYAI | NEUP |
|---|---|---|
| Revenue CAGR (5Y) | -5.11% | 11.12% |
| Total return CAGR (5Y) | -38.53% | N/A |
Frequently asked
- Which has grown faster, DYAI or NEUP?
- Over the past five years, NEUP grew revenue faster — DYAI at a -5.11% CAGR versus NEUP at 11.12%.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.